Creating & Targeting Cancer-Specific Neoantigens with Covalent Inhibitors to Combine IO with Traditional Inhibition Approaches

Time: 11:15 am
day: Day Two Track A AM


  • Showcasing how covalent drugs such as KRAS(G12C) inhibitors can be designed to create cancer-specific neoantigens that can be targeted
  • Displaying how antibodies that selectively recognize drug-peptide conjugates presented by multiple MHC types can be engineered to increase immune involvement
  • Understanding how KRAS(G12C) drug resistant cancer cells can be selectively killed with bispecific T-cell engager antibodies
  • Unlocking the potential of targeted and immune therapies by combining them through this “HapImmune” technology